The purpose of this protocol is to investigate, using functional magnetic resonance imaging (fMRI), the effect of treatment with lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's downstream metabolic effects.
The purpose of this protocol is to investigate the effect of treatment with the study drug, called lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's other metabolic effects. Lorcaserin's effect on the brain will be investigated using functional magnetic resonance imaging (fMRI). Lorcaserin was approved in June 2012 as an addition to a reduced-calorie diet and exercise, for chronic weight management. Previous weight loss drugs, such as fenfluramine, acted throughout the body and caused heart problems. Lorcaserin is different because it only acts on receptors (sites of action) that are found in the brain and does not act on the heart, and thus, has not been shown to cause the heart problems seen in the past. 1. To examine the effects of the study drug lorcaserin, on the brain, and its impact on food visualization (high fat and low fat images) and interaction with satiety (by measuring during the fasting or fed states) using fMRI. (Satiety is defined as when a person has had enough or too much food and does not want to eat any more, as after finishing a satisfying meal.) 2. To examine the satiety and weight-reducing effect of lorcaserin using physiological measurements (such as how much weight is lost and how this may affect hormone levels), and its association with changes in fMRI responses and neuropsychological performance. To examine whether the long-term weight reducing effects of lorcaserin can be predicted by early food visualization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
fMRI (Functional changes in the brain)
Time frame: 28 days
Body Composition (DEXA)
Changes in body composition will be assessed by the following measurements: DEXA (Dual Energy X-Ray Absorptiometry): Body composition and bone density will be measured by DEXA. For the DEXA test, the subject will be lying on an examination bed for about 25 minutes. A small part of the DEXA machine will be recording and moving back and forth about 3 feet above their body. The radiation the subject will get is very small and is much less than what one gets from a regular chest X-Ray. Anthropometry: Anthropometry will be performed by a licensed dietician. Measurements include: Height, Weight, umbilical and smallest waist, broadest and iliac hip measurements.
Time frame: 6 months
Metabolic Rate (Resting Metabolic Rate (RMR)
Resting Metabolic Rate (RMR): RMR is the amount of calories the subject burn without doing any physical work. The subject's RMR will be measured with a commonly used instrument. The subject will be asked to lie quietly in bed and stay awake with a large plastic hood over the subject's head and upper body for about 20 minutes. The subject will breathe normally while the air they breathe out is collected and analyzed.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.